SUVENPHAR2024-10-012024-12-31 SUVENPHAR2024-10-012024-12-31 SUVENPHAR2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member SUVENPHAR2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member SUVENPHAR2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543064 SUVENPHAR NA Suven Pharmaceuticals Limited Equity 2024-04-01 2025-03-31 2025-02-12 2024-12-28 INR Crores Third quarter 15:25:00 16:15:00 2025-02-12 2025-02-12 Not applicable Single segment Contract Development and Manufacturing 2024-10-01 2024-12-31 Unaudited Standalone 2753900000.00 151800000.00 2905700000.00 551100000.00 0.00 -79700000.00 503400000.00 26000000.00 134400000.00 624500000.00 1759700000.00 1146000000.00 0.00 1146000000.00 417900000.00 -135400000.00 282500000.00 0.00 863500000.00 0.00 0.00 0.00 0.00 863500000.00 -900000.00 862600000.00 862600000.00 0.00 254560000.00 1 3.39 3.37 0.00 0.00 3.39 3.37 Notes 1) The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 12 Feb 2025. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion. The financial results for the quarter and nine months ended 31 Dec 2023 and year ended 31 March 2024 were reviewed/audited by Karvy & Co., Chartered Accountants ('predecessor auditors'). 2) The above financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Reg 33 of the SEBI (LODR) Regulations, 2015 (as amended). 3)The Company reportable activity falls under single operating segment i.e. Manufacturing (CRAMS) - Bulk Drugs & Intermediates & Services, hence segment reporting as per Ind AS 108 (Operating Segment) is not presented. 6) The Board of Directors had approved on 29 Feb 2024, the Scheme of Amalgamation of Cohance Life Sciences ltd (Transferor Company) into and with Suven Pharmaceuticals Ltd (‘The Company’). Based on the NCLT order dated 22 October 2024, meetings of the equity shareholders of both the Transferor Company and the Transferee Company were held on 28 Nov 2024 to consider and approve the Scheme. The Scheme has been approved by the Members of the Company with requisite majority. The Scheme of Amalgamation remains subject to applicable approvals, including approvals from the Hon'ble NCLT, and such other approvals, permissions, and sanctions of regulatory and other authorities, as may be applicable. 7) The Board of directors of Suven Pharmaceuticals Ltd ( Company / Transferee Company ) has approved on 29 Feb 2024, the scheme of amalgamation of Casper Pharma Pvt Ltd ( Transferor Company ) (a wholly owned subsidiary of the Company) into and with the Company under the provisions of Sections 230 to 232 of the Companies Act, 2013 subject to receipt of applicable approval including approval from Hon’ble NCLT ( Scheme of Amalgamation ). The Hon’ble NCLT, Mumbai vide its Order dated 24 Oct 2024 has sanctioned the Scheme of Amalgamation. The Company has filed the certified copy of the Order with Registrar of Companies on 4 Dec 2024. As per the Scheme, the Appointed date which is also the effective date of the Scheme has been determined as 1 Jan 2025. Accordingly, the Scheme shall be accounted from the Appointed/ Effective date i.e. 1 Jan 2025 and in the manner prescribed under the scheme. 8) The figures of the previous year/periods have been regrouped/recast to render the classification comparable with that of current period. 9) The financial results for the quarter and nine months ended 31 Dec 2023 and for the year ended 31 Mar 2024 were presented in INR Lakhs. With effect from quarter ended 30 June 2024, the Company has presented the financial results in INR cr. Consequently, the results for the comparative periods have also been presented in INR Cr. Single segment 2024-04-01 2024-12-31 Unaudited Standalone 7335400000.00 465600000.00 7801000000.00 1290100000.00 0.00 208400000.00 1374600000.00 56700000.00 377300000.00 1467200000.00 4774300000.00 3026700000.00 0.00 3026700000.00 897200000.00 -148000000.00 749200000.00 0.00 2277500000.00 0.00 0.00 0.00 0.00 2277500000.00 -1600000.00 2275900000.00 2275900000.00 0.00 254560000.00 1 8.95 8.91 0.00 0.00 8.95 8.91 Other expenses 624500000.00 Other expenses 1467200000.00 -1100000.00 -2100000.00 -200000.00 -500000.00